UniPrint Partners with Healthcare IT Security Leader, Imprivata, to Enable Clinicians To Securely Print Protected Health Information
UniPrint.net Corp., the world leader in printing virtualization, today announced a partnership with Imprivata®, the healthcare IT security company. UniPrint.net has joined the Imprivata Developer Partner (IDP) program, utilizing the Imprivata OneSign® Print Connector to establish connectivity between UniPrint’s™ patented Universal Printer Driver and Virtual Print Queue, and Imprivata OneSign. This integrated solution enables clinicians that use virtual desktops, to securely and conveniently print Protected Health Information (PHI) to any printer, by using the same proximity card they use to log in and securely access patient data. The joint solution increases security and compliance for healthcare providers by eliminating the printing of private health information on unattended printers.
Traditionally, location-based printing has been a challenge for even the most efficient hospitals. Healthcare professionals may inadvertently send prescriptions and private patient data to print on the wrong printer or a printer in a different facility, potentially exposing PHI and violating regulatory requirements.
David Fung, CEO of UniPrint.net comments, “Imprivata OneSign streamlines access, giving healthcare providers increased productivity, better compliance, stronger security, and reduced IT costs. Caregivers can now spend more time with patients and less time signing on to systems. When Imprivata OneSign is deployed in a virtual environment, a user’s desktop follows them as they roam around the workplace. An essential part of that workflow optimization is enabling secure, on demand printing to the correct printer. With a proven track record in healthcare, UniPrint is ideally suited to provide mobile healthcare workers with the ability to conveniently and securely print documents.”
Imprivata OneSign gives millions of care providers fast and secure No Click Access® to the applications and patient information they need, whenever and wherever they need it. By integrating with the
Imprivata OneSign Print Connector, UniPrint’s Universal Printer Driver and Virtual Print Queue leverages Imprivata OneSign’s clinical identity and authentication policy management capabilities and offers error-free, secure mobile printing on demand. Clinicians can print their documents using the same proximity card they use to securely access any endpoint and patient records.
“When healthcare providers are dealing with confidential patient information, they need a trusted, proven solution to address their secure printing needs,” said Clay Ritchey, Chief Marketing Officer at Imprivata. “Printing is often an overlooked vulnerability in healthcare organizations and we’re pleased that UniPrint is able to provide the secure printing workflow within Imprivata OneSign to add another layer of security for our joint customers.”
The solution will be introduced at the upcoming VMworld Conference in Las Vegas, USA, August 28-31. Come by the UniPrint Booth #657 to view a product demo, or to the Imprivata Booth #862 for additional information. Alternatively, visit www.uniprint.net to learn more about UniPrint.net, or book a free demo of our Healthcare Printing Suite.
UniPrint.net is the recognized leader in printing virtualization. The newest solution in UniPrint’s patented, award-winning product line, UniPrint Infinity is the industry’s first truly secure enterprise-wide solution for any computing environment. Enabling anywhere, anytime, and any device secure pull printing, UniPrint Infinity comes with a proven ROI through its statistics module, print document archiving functionality, secure mobile printing modules, and high availability setup with load balancing capability. UniPrint Infinity replaces all manufacturer printer drivers with a single PDF generator to promote faster, more efficient printing, helping organizations to improve both productivity and return on investments.
UniPrint™ and UniPrint Infinity™ are the trademarks of UniPrint.net Corp. All other trademarks and registered trademarks are properties of their respective owners.
Imprivata® (NYSE: IMPR), the healthcare IT security company, provides healthcare organizations globally with a security and identity platform that delivers authentication management, fast access to patient information, secure communications, and positive patient identification. Imprivata enables care providers to securely and efficiently access, communicate, and transact patient health information to address critical compliance and security challenges while improving productivity and the patient experience. For more information, please visit www.imprivata.com.
Katherine Cheung, +1-416-503-9800 x 8586
John Hallock, 617-615-7712
Kerry Pillion, 781-761-1452
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00 | Pressemelding
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26 | Pressemelding
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05 | Pressemelding
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03 | Pressemelding
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and